STAT3 and colorectal carcinoma: Together with the described capacity of IL-17A to inhibit the expression of CXCR3 in CD8+ T cells via STAT3 signaling, the acquired results thus implicated that Th17 cell-released IL-17A is able to dampen the immunological control of CRC disease via the IL-17A/STAT3/CXCR3 axis [74].